Ajrccm: a new treatment for cystic fibrosis

December 5, 2019 / Biovalley / according to a recent study, a new treatment for cystic fibrosis (CF) has been shown to reduce inflammation, which may reduce the need for lung transplantation and reduce the risk of death The study was led by researchers at rcsi, the Royal College of surgery in Ireland, and the results were published in the American Journal of respiratory and critical care medicine Cystic fibrosis (CF) is a genetic disease affecting about 70000 people worldwide The main cause of death in patients with CF is lung disease caused by severe inflammation and chronic respiratory infection (image source: www Pixabay Com) although several new therapies have emerged in recent years to improve lung function and survival rate, there is still a lack of effective anti-inflammatory and anti infection treatment for patients Recently, researchers found that there is one of the most aggressive bacteria in the lungs of CF patients, which can change the metabolism level of some immune cells and promote their production of pro-inflammatory factors In addition, they found that high levels of pro-inflammatory proteins were associated with decreased lung function and an increased risk of death The team then used a small molecule called "mcc950" to reduce the expression of pro-inflammatory proteins in CF mice The results show that this treatment can not only reduce inflammation, but also help to remove bacteria from the lung This marks the first time that researchers have been able to alleviate the disease by targeting cell metabolism, which may help to develop new methods for the treatment of inflammatory diseases such as CF "Previously, life expectancy in CF patients was very low These people are now living longer lives as a result of improved drug treatment However, they still suffer from very serious diseases We hope that this finding will further improve the quality of life of patients and eventually enable them to achieve normal life expectancy, "said Dr Oliver mcelvani, lead author of the study Source of information: new approach to treating chronic fibrosis could lower risk of lung transplants and death source: Oliver J mcelvaney, Zbigniew zaslona, Katrin Becker flegler, EVA M parsson McDermott, Fiona Boland, Cedric gunaratnam, Erich gulbins, Luke A O'Neill, emer P Reeves, Noel G McElvaney Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis American Journal of Respiratory and Critical Care Medicine , 2019; 200 (11): 1381 DOI: 10.1164/rccm.201905-1013OC